论文部分内容阅读
目的：检测１１０ 例疗前肺癌标本多药耐药相关蛋白（ ＭＲＰ） 的表达与预后的关系。方法：采用免疫组化法。结果：ＭＲＰ 总检出率６３ ．６ ％ （７０／１１０） ，ＳＣＬＣ、ＮＳＣＬＣ 分别为４６ ．７ ％ （７／８） 和６５ ．３ ％ （６２／９５） 。尽管鳞癌ＭＲＰ 的表达（７２ ．４ ％ ） 略高于腺癌（５８ ．３ ％ ） ， 但ＭＲＰ 的表达与病理类型、ＴＮＭ 分期及鳞癌、腺癌的分化程度无关。９０ 例接受化疗，７３ 例ＮＳＣＬＣ 中ＭＲＰ（ － ） 者及ＭＲＰ（ ＋ ～＋ ＋ ） 者中位生存期分别为１８ ．９ 个月和１２ ．６ 个月，Ｌｏｇ － Ｒａｎｋ ｔｅｓｔ 及Ｋａｐｌａｎ － Ｍｅｉｅｒ 生存曲线均示ＭＲＰ（ － ） 者较ＭＲＰ（ ＋ ～＋ ＋ ） 者有生存期优势（ Ｐ＜ ０ ．０２） ；３４ 例鳞癌中，ＭＲＰ（ － ）者生存率明显高于ＭＲＰ（ ＋ ～＋ ＋ ） 者。但ＭＲＰ 表达与腺癌预后无关。结论：ＭＲＰ 可能为鳞癌的负性预后因子。
Objective: To examine the relationship between the expression of multidrug resistance-associated protein (MRP) and prognosis in 110 pre-treatment lung cancer specimens. Methods: Immunohistochemistry was used. Results: The total detection rate of MRP 63. 6 % (70/110), SCLC and NSCLC were 46. 7 % (7/8) and 65. 3% (62/95). Although the expression of MRP in squamous cell carcinoma (72.4 %) was slightly higher than that in adenocarcinoma (58. 3 %), the expression of MRP was not associated with pathological type, TNM stage, and the degree of differentiation of squamous cell carcinoma and adenocarcinoma. In 90 patients undergoing chemotherapy, the median survival of MRP (-) and MRP (+-+ +) in 73 NSCLC patients was 18%. 9 months and 12. At 6 months, Log-rank test and Kaplan-Meier survival curves showed that MRP(-) had survival advantage over MRP(+-++) (P < .02); in 34 cases of squamous cell carcinoma, MRP ( - The survival rate was significantly higher than that of MRP (+ - + +). However, MRP expression has nothing to do with the prognosis of adenocarcinoma. Conclusion: MRP may be a negative prognostic factor for squamous cell carcinoma.